Departments of Urology and Obstetrics & Gynecology, New York University, New York, NY.
Departments of Urology and Obstetrics & Gynecology, New York University, New York, NY.
Urology. 2019 Sep;131:71-76. doi: 10.1016/j.urology.2019.04.050. Epub 2019 Jun 20.
To investigate trends in stress urinary incontinence (SUI) surgery before and after the 2011 Foods and Drug Administration notification and the 2014 (American Urogynecologic Society [AUGS]/Society for Urodynamics Female Pelvic Medicine and Urogenital Reconstruction [SUFU]) position statement.
A retrospective chart review was performed to identify patients presenting for evaluation of SUI by 2 Female Pelvic Medicine and Reconstructive Surgery specialists between June 1, 2010 and May 31, 2017. Rates of surgical treatment modality (synthetic midurethral slings [MUS] versus autologous fascial pubovaginal sling versus bulking agents) were analyzed at 6-month intervals.
Over fourteen 6-month intervals, the number of new patients presenting for evaluation of SUI increased consistently. There was a decrease in the proportion of new patients who underwent antiincontinence surgical procedures, specifically MUS, between December 2011 and December 2013. After the integration of the 2014 AUGS/SUFU position statement in patient counseling, this trend reverted and we noted a sustained increase in the proportion of patients electing surgical management. This paralleled an increase in new patient visits for SUI and MUS. The number autologous fascial pubovaginal sling remained stable throughout the study period. Conversely, MUS composed the highest proportion of procedures performed, accounting for 60 %-87.2% off all antiincontinence procedures.
After the Foods and Drug Administration Public Health Notification in 2011, we observed a decline in the number of new patients presenting with SUI electing surgical management, specifically MUS. However, after the AUGS/SUFU position statement publication and integration into counseling, we observed a reversal in the previous year's trends, noting a resurgence of MUS utilization.
研究食品和药物管理局(FDA)2011 年通知和 2014 年(美国妇科泌尿协会[AUGS]/女性盆底医学和泌尿生殖重建协会[SUFU])立场声明发布前后压力性尿失禁(SUI)手术的趋势。
对 2 名女性盆底医学和重建外科专家在 2010 年 6 月 1 日至 2017 年 5 月 31 日期间为评估 SUI 而就诊的患者进行回顾性图表审查。分析每 6 个月的手术治疗方式(合成尿道中段吊带[MUS]与自体筋膜耻骨阴道吊带与填充剂)的比例。
在 14 个 6 个月的间隔内,新出现评估 SUI 的患者数量持续增加。2011 年 12 月至 2013 年 12 月间,接受抗失禁手术(特别是 MUS)的新患者比例有所下降。在将 2014 年 AUGS/SUFU 立场声明纳入患者咨询后,这一趋势逆转,我们注意到选择手术治疗的患者比例持续增加。这与 SUI 和 MUS 新患者就诊人数的增加相吻合。整个研究期间,自体筋膜耻骨阴道吊带的数量保持稳定。相反,MUS 构成了所行手术中比例最高的部分,占所有抗失禁手术的 60%-87.2%。
2011 年 FDA 公共卫生通知发布后,我们观察到新出现 SUI 并选择手术治疗的患者数量,特别是 MUS 数量有所下降。然而,在 AUGS/SUFU 立场声明发布并纳入咨询后,我们观察到前一年的趋势逆转,MUS 的使用再次增加。